Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
8 min read
Multifocal motor neuropathy Indication Strategy Report 2026: C1s, Trials and Deals
23 July 2026
2026 Multifocal motor neuropathy strategy: epidemiology, C1s biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Secondary progressive multiple sclerosis Indication Strategy Report 2026: BTK, Trials and Deals
23 July 2026
2026 Secondary progressive multiple sclerosis strategy: epidemiology, BTK biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Primary progressive multiple sclerosis Indication Strategy Report 2026: CD20, Trials and Deals
23 July 2026
2026 Primary progressive multiple sclerosis strategy: epidemiology, CD20 biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Myoclonus-dystonia Indication Strategy Report 2026: SGCE, Trials and Deals
23 July 2026
2026 Myoclonus-dystonia strategy: epidemiology, SGCE biology, clinical competition, recent deals, unmet need and market attractiveness. Evidence synthesized with…
Latest Hotspot
8 min read
DYT1 dystonia Indication Strategy Report 2026: TOR1A, Trials and Deals
23 July 2026
2026 DYT1 dystonia strategy: epidemiology, TOR1A biology, clinical competition, recent deals, unmet need and market attractiveness. Evidence synthesized with…
Latest Hotspot
8 min read
Alternating hemiplegia of childhood Indication Strategy Report 2026: ATP1A3, Trials and Deals
23 July 2026
2026 Alternating hemiplegia of childhood strategy: epidemiology, ATP1A3 biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
GLUT1 deficiency syndrome Indication Strategy Report 2026: SLC2A1, Trials and Deals
23 July 2026
2026 GLUT1 deficiency syndrome strategy: epidemiology, SLC2A1 biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
PCDH19 epilepsy Indication Strategy Report 2026: GABA-A receptor, Trials and Deals
23 July 2026
2026 PCDH19 epilepsy strategy: epidemiology, GABA-A receptor biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
STXBP1 encephalopathy Indication Strategy Report 2026: STXBP1, Trials and Deals
23 July 2026
2026 STXBP1 encephalopathy strategy: epidemiology, STXBP1 biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Landau-Kleffner syndrome Indication Strategy Report 2026: GRIN2A, Trials and Deals
23 July 2026
2026 Landau-Kleffner syndrome strategy: epidemiology, GRIN2A biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Ohtahara syndrome Indication Strategy Report 2026: STXBP1, Trials and Deals
23 July 2026
2026 Ohtahara syndrome strategy: epidemiology, STXBP1 biology, clinical competition, recent deals, unmet need and market attractiveness. Evidence synthesized…
Latest Hotspot
8 min read
Infantile spasms Indication Strategy Report 2026: mTOR, Trials and Deals
23 July 2026
2026 Infantile spasms strategy: epidemiology, mTOR biology, clinical competition, recent deals, unmet need and market attractiveness. Evidence synthesized with…